uniQure (QURE) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is QURE's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

The FDA reversed its support for natural-history controls, demanded a sham-controlled trial, then reversed course again, delaying progress for months while Huntington's patients continued suffering irreversible decline. …

uniQure NASDAQ: QURE Chief Executive Matt Kapusta said investors are focused on regulatory risk surrounding its experimental Huntington's disease therapy, AMT-130, but may be underestimating the need for treatment and th…

uniQure shares rally 17.5% as FDA grants Priority Review to its Huntington's disease gene therapy, but it remains to be seen if clinical and regulatory progress can sustain momentum.…

uniQure NASDAQ: QURE is preparing for a potential U.S. advisory committee meeting on AMT-130, its experimental gene therapy for Huntington's disease, after regulators accepted its biologics license application for priori…

uniQure NASDAQ: QURE said the FDA has accepted its Biologics License Application for AMT-130, an investigational treatment for Huntington's disease, and granted the application Priority Review with a target action date o…

uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript…

uniQure (QURE) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $1.38 per share a year ago.…

~ FDA granted priority review of BLA for ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~…

uniQure's stock has come under significant pressure again after the company reported mixed 4-year AMT-130 data. While measurement noise and control bias likely explain much of the disappointing results, there is now grea…

The U.S. Food and Drug Administration has accepted uniQure NV's (NASDAQ:QURE) Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's disease submitted under t…

~ FDA sets PDUFA target action date of May 1, 2027 ~ ~ If approved, ifezuntirgene inilparvovec will be the world's first disease-modifying treatment for Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02, 202…

Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.…

~ uniQure to host earnings call on Wednesday, November 4, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Wednesday, November 4, 2026 at 8:30 a.m. ET ~…

uniQure (QURE) is rated a Speculative Buy with a $47 price target, implying 115% upside. QURE's Huntington's gene therapy BLA is under FDA accelerated review, with a decision expected around November 1. Three-year data m…

New York, New York--(Newsfile Corp. - October 13, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) investors concerning the Com…

Vir Biotechnology (NASDAQ: VIR - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the stre…

During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Gr…

NEW YORK--(BUSINESS WIRE)---- $QURE #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) investors concerni…

uniQure N.V. (NASDAQ: QURE - Get Free Report)'s share price was down 5.5% on Tuesday after Barclays downgraded the stock from an overweight rating to an equal weight rating. Barclays now has a $28.00 price target on the …

Alkermes (NASDAQ: ALKS - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their anal…

Shares of uniQure N.V. (NASDAQ: QURE - Get Free Report) gapped down prior to trading on Monday after Barclays downgraded the stock from an overweight rating to an equal weight rating. The stock had previously closed at $…

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). The investigation concerns whether the …

QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.…

On Tuesday, Sep. 29, uniQure reported four-year AMT-130 data for Huntington's Disease that included cUHDRS & TFC four-year data. cUHDRS at year 4 showed 44% slowing, with a non-significant p=0.144. Per QURE, this may hav…

uniQure's four-year AMT-130 Huntington's disease benefit came in smaller than its three-year result, and QURE shares plummeted. SueWallSt notifies investors of a pending investigation into potential securities law violat…

LOS ANGELES--(BUSINESS WIRE)---- $QURE--QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law.…

PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C.…

~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of dise…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

